Amgen Pushes Back Against UK Tavneos Suspension

Amgen has pushed back against the UK's decision to suspend the use of Tavneos for new patients. The drug, which is used to treat adult patients with a certain type of autoimmune disease, was suspended in September due to concerns over its safety.

The company stated that it understands the need for regulatory agencies to scrutinize data and take necessary actions to protect public health.

However, Amgen expressed disappointment at the UK's decision, highlighting the importance of Tavneos as a treatment option for patients with severe autoimmune diseases.